Pfizer recalls certain lots of blood pressure medications due to carcinogen risk
Click Here to Manage Email Alerts
Pfizer has issued a voluntarily recall of certain lots of quinapril HCl/hydrochlorothiazide tablets and additional lots distributed by Greenstone due to high levels of a nitrosamine known to be carcinogenic in high doses.
According to an FDA press release, N-nitroso-quinapril was found in higher than acceptable daily levels in six lots of quinapril HCl/hydrochlorothiazide tablets (Accuretic) distributed by Pfizer and two lots of quinapril and hydrochlorothiazide and six lots of quinapril HCl/ hydrochlorothiazide generics distributed by Greenstone. The medications are for lowering BP.
The recalled lots were distributed in the U.S. and Puerto Rico between November 2019 and March 2022.
Although nitrosamines are common in water and certain foods, exposure to higher than acceptable levels over long periods of time may increase risk for cancer, according to the release.
Pfizer has not received any reports of adverse events associated to the recalled drug and, according to the release, there is no immediate risk to patients taking this drug.
Please see the FDA release for more information about the recalled lots.
Read more about
Click Here to Manage Email Alerts